Getting regulatory approval in Brazil feels like the finish line for many manufacturers. Months of preparation. Documentation. Technical files. Interactions with ANVISA. When the approval finally comes through, the natural reaction is simple: Great. Now we can start selling. But Brazil doesn’t quite work that way. Regulatory approval is important. Absolutely necessary. It’s just not the moment the market opens. In reality, approval is the moment the next phase begins. Approval allows entry. It doesn’t guarantee adoption. We’ve watched this pattern many times. A manufacturer receives ANVISA approval and expects the commercial process to move quickly. After all, the product is now legally authorized in the country. Hospitals should be ready. Distributors should be eager. Sales should follow. And yet, months later, adoption is slower than expected. Sometimes much slower. Why? Because hospital adoption in Brazil depends on a set of dynamics that exist beyond regulatory approval. Understanding those dynamics early makes an enormous difference. Hospitals don’t buy approvals. They buy solutions. From a regulatory perspective, approval means the product meets safety and performance requirements. From a hospital’s perspective, that’s just the starting point. Procurement teams, clinical committees, and hospital administrators evaluate different questions: How does this technology compare with existing alternatives? Does it improve clinical outcomes? Does it reduce operational costs or complications? How does it fit into current clinical protocols? In many institutions, new technologies must also pass through clinical evaluation committees before being incorporated into purchasing lists. That process takes time. Relationships matter. Clinical evidence matters. Physician advocacy matters. Approval opens the door. Adoption requires a different kind of work. The importance of the right distribution structure Another factor that shapes adoption is distribution. Brazil’s healthcare system is geographically vast and commercially fragmented. Thousands of hospitals operate under different purchasing models private networks, independent hospitals, regional groups, and public institutions. No single distributor reaches them all effectively. Manufacturers who succeed here usually build distribution strategies designed around market access, not just logistics. That means working with partners who understand: hospital procurement dynamics clinical engagement local reimbursement realities and the nuances of regional healthcare markets In other words, distribution in Brazil isn’t just about delivering products. It’s about opening doors. Clinical champions often make the difference One of the most underestimated drivers of hospital adoption in Brazil is physician advocacy. When clinicians understand a technology, trust its performance, and see value for their patients, adoption accelerates. Without that clinical engagement, even well positioned products can take much longer to gain traction. Manufacturers entering Brazil often underestimate the importance of building relationships with key physicians and clinical opinion leaders early in the process. But in practice, those relationships often determine how quickly hospitals incorporate new technologies. Market access is a journey Regulatory approval, distribution partnerships, physician engagement, hospital procurement. Each of these steps plays a role in turning an approved product into a product that is actually used inside hospitals. And the timeline between approval and adoption can vary widely depending on how these elements come together. Some manufacturers reach hospital adoption quickly because they planned the commercial strategy early. Others spend months adjusting the structure after approval. Not because the product lacks value. But because market access requires more than regulatory clearance. Brazil rewards preparation Brazil is one of the most attractive healthcare markets in Latin America. Large hospital networks. Advanced clinical centers. Growing demand for medical technology. But like many complex markets, success usually belongs to manufacturers who think beyond the first milestone. Approval matters. Adoption matters more. And the companies that prepare for both from the beginning are the ones that build sustainable growth in the Brazilian market. Thinking about Brazil? Every product follows a slightly different path to hospital adoption. Different specialties. Different hospital dynamics. Different procurement realities. But the journey from regulatory approval to real clinical use always involves more than one step. If Brazil is part of your international strategy, it’s worth mapping that journey carefully from the start.
It can make the difference between entering the market… and truly establishing a presence in it.
Find out more about BPO in RA!
*Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br
